Search clinical trials for: GSK Bio's influenza vaccine GSK2340272A

Total 14246 results

GlaxoSmithKline

Completed

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

Influenza

Canada
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

France, Spain, Germany, Russian Federation, Estonia, Sweden, Netherlands
GlaxoSmithKline

Completed

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
Oswaldo Cruz Foundation
Ministry of Health, Brazil

Completed

Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults (VIP-H1N1)

HIV Infection

Brazil
GlaxoSmithKline

Completed

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Russian Federation, Germany, France, Greece, United Kingdom, Norway, Estonia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

Influenza

Czechia
GlaxoSmithKline

Completed

Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations

Influenza

Estonia
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate

Influenza

Norway
GlaxoSmithKline

Completed

Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

Influenza

United States
GlaxoSmithKline

Completed

Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children

Influenza

United States
GlaxoSmithKline

Completed

Study to Evaluate an Influenza Vaccine Candidate

Influenza

Finland, Greece
GlaxoSmithKline

Completed

Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A

Influenza

Germany, Sweden, United Kingdom, Netherlands
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

Influenza

United States, Germany, Poland, Spain, Czechia, Bangladesh, France
GlaxoSmithKline

Completed

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

United Kingdom
GlaxoSmithKline

Completed

Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Philippines
GlaxoSmithKline

Completed

Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

China
GlaxoSmithKline

Completed

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

Infections, Meningococcal

South Africa
GlaxoSmithKline

Completed

Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Singapore
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

China
GlaxoSmithKline

Completed

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Haemophilus Influenzae Type b

China
GlaxoSmithKline

Terminated

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Slovakia
GlaxoSmithKline

Terminated

Effectiveness of Flu Vaccination and Burden of Illness Among Community-dwelling Elderly With Influenza Like Illness in Brazil

Influenza

Brazil
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Herpes Zoster

Germany, Canada, United States
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

Influenza

Belgium, France
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly

Influenza

Belgium
GlaxoSmithKline

Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain, Germany, Poland
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

Dengue

Thailand
GlaxoSmithKline

Completed

Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom (H1N1 PASS UK)

Influenza

United Kingdom
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

Influenza

United States, Canada
GlaxoSmithKline

Terminated

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

Haemophilus Influenzae | Streptococcus Pneumoniae

Canada
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

Influenza

Brazil
GlaxoSmithKline

Completed

Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

India
GlaxoSmithKline

Completed

Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine

Haemophilus Influenzae Type b Disease

China
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Respiratory Disorders

Australia
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
GlaxoSmithKline

Completed

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

Influenza

Germany, United States, Belgium, Norway

3

Subscribe